Tumor Protein D52 (TPD52) and Cancer-oncogene Understudy or Understudied Oncogene?

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 May 7

PMID 24798974

Citations 39

Authors

Jennifer A Byrne

Sarah Frost

Yuyan Chen

Robert K Bright

Affiliations

Soon will be listed here.

Abstract

The Tumor protein D52 (TPD52) gene was identified nearly 20 years ago through its overexpression in human cancer, and a substantial body of data now strongly supports TPD52 representing a gene amplification target at chromosome 8q21.13. This review updates progress toward understanding the significance of TPD52 overexpression and targeting, both in tumors known to be characterized by TPD52 overexpression/amplification, and those where TPD52 overexpression/amplification has been recently or variably reported. We highlight recent findings supporting microRNA regulation of TPD52 expression in experimental systems and describe progress toward deciphering TPD52's cellular functions, particularly in cancer cells. Finally, we provide an overview of TPD52's potential as a cancer biomarker and immunotherapeutic target. These combined studies highlight the potential value of genes such as TPD52, which are overexpressed in many cancer types, but have been relatively understudied.

Citing Articles

Tumor Protein D53 (TPD53): Involvement in Malignant Transformation of Low-Malignant Oral Squamous Cell Carcinoma Cells.

Watanabe M, Mukudai Y, Kindaichi N, Nara M, Yamada K, Abe Y Biomedicines. 2025; 12(12.

PMID: 39767632 PMC: 11727615. DOI: 10.3390/biomedicines12122725.

TPD52 as a Therapeutic Target Identified by Machine Learning Shapes the Immune Microenvironment in Breast Cancer.

Xia J, Zhou X J Cell Mol Med. 2025; 29(1):e70333.

PMID: 39757112 PMC: 11702390. DOI: 10.1111/jcmm.70333.

Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.

Li Y, Tang X, Wang B, Chen M, Zheng J, Chang K Noncoding RNA Res. 2024; 9(4):1351-1362.

PMID: 39247145 PMC: 11380467. DOI: 10.1016/j.ncrna.2024.07.003.

KLF7 enhances the invasion and migration of colorectal cancer cells via the miR-139-5p/TPD52 axis.

Zhang J, Li Z, Han J, Tian Z, Meng Q, Niu W Cancer Biol Ther. 2024; 25(1):2385172.

PMID: 39097779 PMC: 11299624. DOI: 10.1080/15384047.2024.2385172.

TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis.

Miao L, Jing L, Chen B, Zeng T, Chen Y Curr Mol Med. 2024; 24(11):1413-1425.

PMID: 38178662 DOI: 10.2174/0115665240260252230919054858.

References

Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim M . Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics. 2010; 10(21):3800-10. PMC: 4327899. DOI: 10.1002/pmic.201000297. View

Machado I, Lopez-Guerrero J, Calabuig-Farinas S, Hardy J, Scotlandi K, Picci P . Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatr Dev Pathol. 2011; 14(3):255-6. DOI: 10.2350/11-01-0956-LET.1. View

Machado I, Alberghini M, Giner F, Corrigan M, OSullivan M, Noguera R . Histopathological characterization of small cell osteosarcoma with immunohistochemistry and molecular genetic support. A study of 10 cases. Histopathology. 2010; 57(1):162-7. DOI: 10.1111/j.1365-2559.2010.03589.x. View

Chen Y, Kamili A, Hardy J, Groblewski G, Khanna K, Byrne J . Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle. 2013; 12(18):3083-97. PMC: 3875682. DOI: 10.4161/cc.26146. View

Roslan N, Bieche I, Bright R, Lidereau R, Chen Y, Byrne J . TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2013; 53(10):807-19. DOI: 10.1002/mc.22038. View

Kaspar K, Thomas D, Taft W, Takeshita E, Weng N, Groblewski G . CaM kinase II regulation of CRHSP-28 phosphorylation in cultured mucosal T84 cells. Am J Physiol Gastrointest Liver Physiol. 2003; 285(6):G1300-9. DOI: 10.1152/ajpgi.00534.2002. View

Cheng L, Wang P, Yang S, Yang Y, Zhang Q, Zhang W . Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med Genomics. 2012; 5:14. PMC: 3441862. DOI: 10.1186/1755-8794-5-14. View

Nakagawa T, Kollmeyer T, Morlan B, Anderson S, Bergstralh E, Davis B . A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008; 3(5):e2318. PMC: 2565588. DOI: 10.1371/journal.pone.0002318. View

Aure M, Steinfeld I, Baumbusch L, Liestol K, Lipson D, Nyberg S . Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PLoS One. 2013; 8(1):e53014. PMC: 3559658. DOI: 10.1371/journal.pone.0053014. View

10.

Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C . Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008; 275(22):5703-13. DOI: 10.1111/j.1742-4658.2008.06697.x. View

11.

Niu N, Qin Y, Fridley B, Hou J, Kalari K, Zhu M . Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20(11):1482-92. PMC: 2963812. DOI: 10.1101/gr.107672.110. View

12.

Kern S . Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012; 72(23):6097-101. PMC: 3513583. DOI: 10.1158/0008-5472.CAN-12-3232. View

13.

Flores R, Li Y, Yu A, Shen J, Rao P, Lau S . A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol. 2012; 6:50. PMC: 3431263. DOI: 10.1186/1752-0509-6-50. View

14.

Lewis J, Payton L, Whitford J, Byrne J, Smith D, Yang L . Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res. 2007; 5(2):133-44. DOI: 10.1158/1541-7786.MCR-06-0245. View

15.

Mohseny A, Machado I, Cai Y, Schaefer K, Serra M, Hogendoorn P . Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011; 91(8):1195-205. DOI: 10.1038/labinvest.2011.72. View

16.

Bright J, Schultz H, Byrne J, Bright R . Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. Oncoimmunology. 2013; 2(7):e25049. PMC: 3782160. DOI: 10.4161/onci.25049. View

17.

Kourtidis A, Jain R, Carkner R, Eifert C, Brosnan M, Conklin D . An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res. 2010; 70(5):1783-92. PMC: 2837372. DOI: 10.1158/0008-5472.CAN-09-1550. View

18.

Aquino P, Fischer J, Neves-Ferreira A, Perales J, Domont G, Araujo G . Are gastric cancer resection margin proteomic profiles more similar to those from controls or tumors?. J Proteome Res. 2012; 11(12):5836-42. DOI: 10.1021/pr300612x. View

19.

Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S . Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer. 2001; 32(2):164-71. DOI: 10.1002/gcc.1178. View

20.

Byrne J, Chen Y, Martin La Rotta N, Peters G . Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. Genes Cancer. 2012; 3(2):87-101. PMC: 3463919. DOI: 10.1177/1947601912456287. View